Outcome of patients with refractory/relapsed AML salvaged with the MEC (Mitoxantrone Etoposide Cytarabine) regimen.

被引：0
|
作者：
Castagnola, C [1 ]
Alessandrino, EP [1 ]
Pagnucco, G [1 ]
Bernasconi, P [1 ]
Lunghi, M [1 ]
Colombo, A [1 ]
Brusamolino, E [1 ]
Bonfichi, M [1 ]
Corso, A [1 ]
Lazzarino, M [1 ]
Bernasconi, C [1 ]
机构：
[1] Univ Pavia, IRCCS, Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4627
引用
收藏
页码：210B / 210B
页数：1
相关论文
共 50 条
  • [21] A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia
    Christian, Sonia
    Arain, Saad
    Patel, Pritesh
    Khan, Irum
    Calip, Gregory S.
    Agrawal, Vaibhav
    Sweiss, Karen
    Griffin, Shawn
    Cahill, Kirk
    Konig, Heiko
    Esen, Aysenur
    Shergill, Ardaman
    Odenike, Olatoyosi
    Stock, Wendy
    Quigley, John G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (08) : 937 - 943
  • [22] MITOXANTRONE, ETOPOSIDE, ARA-C AND LOW DOSE GEMTUZUMAB OZOGAMICIN (MY-MEC) AS SALVAGE THERAPY FOR RELAPSED-REFRACTORY AML PATIENTS
    Clavio, M.
    Ghiso, A.
    Cagnetta, A.
    Vignolo, L.
    Ghiggi, C.
    Varaldo, R.
    Ballerini, F.
    Aquino, S.
    Olcese, F.
    Miglino, M.
    Lucchetti, M. V.
    Pierri, I.
    Canepa, L.
    Canepa, P.
    Gobbi, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 547 - 547
  • [23] Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC).
    Advani, R
    Saba, HI
    Tallman, M
    Rowe, JM
    Wiernik, PH
    Ramek, J
    Dugan, K
    Lum, B
    Villena, J
    Sikic, BI
    Davis, E
    Paietta, E
    Litchman, M
    Greenberg, P
    BLOOD, 1997, 90 (10) : 2260 - 2260
  • [24] Salvage therapy with Flag/Idarubicin/Mylotarg (Flag-IM) results in a superior CR/CRp rate and low toxicity when compared to Mitoxantrone/Etoposide/Cytarabine (MEC) in patients with relapsed and refractory AML.
    Van Tine, Brian A.
    Augustin, Kristan M.
    Kuperman, David I.
    Nervi, Bruno
    Westervelt, Peter
    DiPersio, John F.
    BLOOD, 2006, 108 (11) : 224B - 224B
  • [25] Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia
    Yamamoto, Chihiro
    Ito, Shoko
    Mashima, Kiyomi
    Umino, Kento
    Minakata, Daisuke
    Yamasaki, Ryoko
    Kawasaki, Yasufumi
    Sugimoto, Miyuki
    Nakano, Hirofumi
    Ashizawa, Masahiro
    Okazuka, Kiyoshi
    Hatano, Kaoru
    Sato, Kazuya
    Oh, Lekuni
    Fujiwara, Shin-Ichiro
    Ohmine, Ken
    Suzuki, Takahiro
    Muroi, Kazuo
    Kanda, Yoshinobu
    LEUKEMIA & LYMPHOMA, 2016, 57 (11) : 2541 - 2547
  • [26] Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Identifies Novel Biomarkers to Inform Mitoxantrone, Etoposide, and Cytarabine (MEC)-Based Combination Therapy in Refractory & Relapsed Acute Myeloid Leukemia (AML) Patients
    Marcucci, Guido
    Kumar, Ansu
    Castro, Michael
    Grover, Himanshu
    Patil, Vivek
    Alam, Aftab
    Azam, Humera
    Mohapatra, Subrat
    Tyagi, Anuj
    Kumari, Pallavi
    Prasad, Samiksha Avinash
    Nair, Prashant Ramachandran
    Lunkad, Neelesh
    Joseph, Vishwas
    Poornachandra, G.
    Chauhan, Jyoti
    Basu, Sayani
    Behura, Liptimayee
    Ghosh, Adity
    Husain, Zakir
    Mandal, Rema
    raman, Rahul K.
    Patel, Sanjana
    Mundkur, Nirjhar
    Christie, James
    Macpherson, Michele Dundas
    Howard, Scott C.
    BLOOD, 2021, 138
  • [27] Etoposide and cytarabine as an effective and safe cytoreductive regimen for relapsed or refractory acute myeloid leukemia
    Nair, G.
    Karmali, R.
    Gregory, S. A.
    Shammo, J. M.
    Fung, H. C.
    Jimenez, A.
    Venugopal, P.
    Larson, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study
    Halpern, Anna B.
    Estey, Elihu H.
    Othus, Megan
    Orlowski, Kaysey F.
    Powell, Morgan A.
    Chen, Tara L.
    Becker, Pamela S.
    Scott, Bart L.
    Hendrie, Paul C.
    Ostronoff, Fabiana
    Ranker, Elizabeth M.
    Shadman, Mazyar
    Stirewalt, Derek L.
    Walter, Roland B.
    BLOOD, 2014, 124 (21)
  • [29] Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)
    Advani, R
    Visani, G
    Milligan, D
    Saba, H
    Tallman, M
    Rowe, JM
    Wiernik, PH
    Ramek, J
    Dugan, K
    Lum, B
    Villena, J
    Davis, E
    Paietta, E
    Litchman, M
    Covelli, A
    Sikic, B
    Greenberg, P
    DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III, 1999, 457 : 47 - 56
  • [30] A multi-institution comparison of mitoxantrone, etoposide, and cytarabine (MEC) vs. high-dose cytarabine and mitoxantrone (Ara-C Couplets) therapy for patients with relapsed or refractory (R/R) acute myeloid leukemia.
    Christian, Sonia
    Patel, Pritesh Rajni
    Griffin, Shawn
    Agrawal, Vaibhav
    Khan, Irum
    Sweiss, Karen
    Shergill, Ardaman
    Konig, Heiko
    Quigley, John G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345